Karyopharm Therapeutics Inc.

  • Vendor Contracts Specialist

    Job Locations US-MA-Newton
    Job ID
    # of Openings
    Regular Full-Time
  • Responsibilities

    • Track, maintain, and update all agreements through their lifecycle using Karyopharm’s contract lifecycle systems
    • QC final drafts to ensure compliance with corporate guidelines and goals.
    • Oversee lifecycle of agreements from request to execution and distribution to all parties.
    • Interface between legal, finance, and clinical operations to move clinical trial agreements to completion.
    • Draft and negotiate simple contracts such as CDAs and amendments.
    • Prepare and administer routine correspondence, negotiation memoranda, and contract documentation.
    • Serve also as in an administrative capacity for all contract matters within the legal department (responsible for execution process, monitoring expiration dates of agreements, and contracts filing in accordance with appropriate records retention procedures.)


    • Bachelor’s degree preferred plus at least (1) year of contracts related experience required
    • Strong written and verbal communication skills.
    • Prioritizing and working independently.
    • Ability to multitask
    • Strong organization and planning skills
    • Being confident, professional, and flexible
    • Being a team player
    • Being energetic and able to handle stress in a fast-paced environment
    • Principles and practices of contract negotiation and compliance;
    • Pertinent Federal, State and local laws, codes and regulations;
    • Corporate policies and procedures.
    • Previous experience in the Biotech/Pharma industry - an advantage


    Karyopharm Therapeutics is a clinical-stage pharmaceutical company, based in Newton, MA, USA, focused on the discovery, development and commercialization of novel, first-in-class agents targeting nuclear transport for the treatment of cancer and other major diseases. Karyopharm is the industry leader in oral Selective Inhibitor of Nuclear Export (SINE) technology, developed to address a central mechanism of oncogenesis via the inhibition of exportins specifically XPO1. Selinexor, Karyopharm’s lead candidate, has been administered to patients with hematologic malignancies or solid tumors in clinical trials worldwide. Karyopharm is currently preparing for its first potential U.S. commercial launch in 2019. 



    Sorry the Share function is not working properly at this moment. Please refresh the page and try again later.
    Share on your newsfeed